Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Needham Downgrades KnowBe4 to Hold

Needham Downgrades KnowBe4 to Hold

Needham analyst Alex Henderson downgrades KnowBe4 (NASDAQ:KNBE) from Buy to Hold.

byBenzinga Newsdesk

October 13, 2022

1 minute read

Needham analyst Alex Henderson downgrades KnowBe4 (NASDAQ:KNBE) from Buy to Hold.

Trump Victory ‘More Bearish’ For Debt Market Than A Biden Win, Warns ‘Bond King’ Bill Gross

By Benzinga Neuro

May 27, 12:59 AM

Bill Gross, the renowned fixed-income investor, has expressed concerns about the potential impact of a Donald Trump re-election on the bond markets.

DJT

Fed’s Mester Says Financial Market Alignment With Fed Much Closer Than Before; Says We’re Going To Have To Do A Little More On Rate

By Benzinga Newsdesk

February 24, 9:09 AM

-CNBC Interview

SPY

Warner Bros. Discovery Expects FY23 Adj EBITDA $10.5B-$11B, Implying an Impact of $300M-$500M Due to Strikes Which Will Continue Through Year End, Sees Q3 FCF Over $1.7B Due to Barbie’s Performance

By Benzinga Newsdesk

September 5, 7:49 AM

Warner Bros. Discovery, Inc. (“WBD” or the “Company”) President and CEO, David Zaslav, will be participating at an investor conference on September 6, 2023 and expects to discuss, among other

WBD

Analyst Ratings

What To Know About RBC Capital’s Downgrade of Sangamo Therapeutics

By Benzinga Insights

November 3, 1:00 PM

RBC Capital downgraded its rating of Sangamo Therapeutics (NASDAQ:SGMO) to Sector Perform with a price target of $2.00,…

SGMO

Needham Downgrades KnowBe4 to Hold

Related Posts

Trump Victory ‘More Bearish’ For Debt Market Than A Biden Win, Warns ‘Bond King’ Bill Gross

Fed’s Mester Says Financial Market Alignment With Fed Much Closer Than Before; Says We’re Going To Have To Do A Little More On Rate

Warner Bros. Discovery Expects FY23 Adj EBITDA $10.5B-$11B, Implying an Impact of $300M-$500M Due to Strikes Which Will Continue Through Year End, Sees Q3 FCF Over $1.7B Due to Barbie’s Performance

What To Know About RBC Capital’s Downgrade of Sangamo Therapeutics